VIKING-MALT-GROUP
3.11.2020 06:32:12 CET | Business Wire | Press release
Teemu Pohjola is appointed CFO of Polttimo and Viking Malt Group effective 3rd of November 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005570/en/
Previously Teemu Pohjola held the position of the CFO of Huhtamäki Fiber and Foodservice segment leading an international team of Finance professionals driving its financial strategy and performance since 2017. Prior to that he has worked in international context for 15 years, holding several strategic finance positions in among others Fazer and Salcomp.
“We are pleased to welcome Teemu to our leadership team,” said Kasper Madsen , CEO of Viking Malt Group. “His deep and extensive experience in leading the financial operations in an international context as well as driving the strategic initiatives will be very valuable for us. He will provide strong leadership and is an excellent addition to the team.”
“I am excited to join a company with a strong business model and a proud history and look forward to working with the team to execute the strategy and vision of the company´s priorities.”
As CFO, Teemu Pohjola will lead the finance organization across the five Viking Malt countries and will be responsible for IT as well as accounting, treasury, financial planning, analysis and tax. He is also the Secretary of Polttimo, Viking Malt and Senson.
Teemu holds a Bachelor degree in Business Administration from Mercuria Business School and MBA from Hanken School of Economics.
Background info
Polttimo Group
Polttimo Group, established in 1883, is an international group of companies, specializing in manufacturing raw materials and raw materials solutions for the food and beverage industry around the world. We create new innovative grain-based solutions for our customers. Our main products are malt for brewing, craft brewing and distilling as well as cereal-based ingredients. Our group consists of Viking Malt Group , the leading Nordic malting company, and Senson Oy , manufacturing malt extracts and flours, cereal extracts, enzymes and many other innovative ingredients.
Viking Malt Group
Viking Malt is the number one malting company in Northern Europe, and the world’s leading company of special malts. A dedicated team, good quality malting barley and six efficient production sites with a capacity of 600 000 tons form the basis for our offering to international and local brewers and distillers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Host 2026 Digital Investor Day10.6.2026 14:30:00 CEST | Press release
SLB (NYSE: SLB) will host an Investor Day on Wednesday, June 17, 2026, in New York, where leadership will outline their vision for SLB’s Digital business as digital technologies and AI continue to reshape the energy industry. The presentation will highlight SLB’s integrated digital strategy and portfolio, scalable growth opportunities powered by AI, and financial profile and outlook. Olivier Le Peuch, chief executive officer, SLB, will present at 9:00 a.m. U.S. Eastern Time (ET), and will discuss SLB’s digital strategy and business outlook. Stephane Biguet, chief financial officer, SLB, will present at approximately 11:00 a.m. ET, and will discuss the financial profile of SLB’s Digital business, the market opportunity and SLB’s 2030 digital ambitions. Mr. Le Peuch and Mr. Biguet will be joined by divisional leadership, who will provide further insight into Digital’s competitive differentiation supported by its mission-critical platform, driving transformation for customers. A live webc
Wolters Kluwer expands its Libra AI workspace with authoritative Swiss legal content from leading publisher Stämpfli10.6.2026 14:00:00 CEST | Press release
Collaboration brings trusted Swiss legal expertise directly into AI‑supported legal research, drafting and review Wolters Kluwer Legal & Regulatory today announced the expansion of Libra by Wolters Kluwer, its AI-powered legal workspace, to include professional legal content from Stämpfli Publishers, one of Switzerland’s most respected legal publishers. As a result, Swiss legal professionals using Libra by Wolters Kluwer gain direct access to the legal literature that shapes their daily work – fully integrated into a single AI-supported workflow. The content offering includes commentaries, practitioner guides, yearbooks and selected journals from Stämpfli Publishers – including the renowned “Berner Kommentar”, and the company’s succinct commentaries and legal textbooks. In addition, primary sources of Swiss law at both federal and cantonal level are integrated into the workspace. The offering will be continuously expanded over time, with additional titles gradually integrated into the
Macrobond Launches AI Data Feed with MCP and Skill, Bringing Governed Macroeconomic Intelligence to Enterprise AI Workflows10.6.2026 14:00:00 CEST | Press release
Two new delivery components, MCP for conversational AI and Skill for programmatic access, enable institutions to retrieve trusted, licensed macroeconomic data directly within their AI environments. Macrobond today announced the general availability of the Macrobond AI Data Feed Service, a purpose-built product, enabling financial institutions to integrate governed macroeconomic intelligence directly into AI-powered research, investment, and strategy workflows. Available now with MCP, Skill and API delivery components, the AI Data Feed helps organizations accelerate macroeconomic research and insight generation and reduce reliance on fragmented or ungoverned data sources. By delivering reliable, licensed, economic data integrated directly within AI chat interfaces and coding environments, the AI Data Feed Service provides a trusted foundation for enterprise AI initiatives. As generative AI becomes embedded in research, investment, and strategy workflows, face a foundational challenge: m
Parse Biosciences Launches the Next Generation of its Immune Profiling Kits10.6.2026 14:00:00 CEST | Press release
Updated kits deliver improved sensitivity and receptor recovery for single cell immune repertoire profiling at unprecedented scale Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale. Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-thro
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 13:47:00 CEST | Press release
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets.It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom